IDEXX Laboratories (NASDAQ:IDXX) Shares Gap Up Following Strong Earnings

IDEXX Laboratories, Inc. (NASDAQ:IDXX) gapped up prior to trading on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $551.21, but opened at $625.00. IDEXX Laboratories shares last traded at $643.2080, with a volume of 380,773 shares changing hands.

The company reported $3.96 earnings per share for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter last year, the business posted $3.22 earnings per share. The business’s revenue for the quarter was up 9.9% on a year-over-year basis.

Key Stories Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported Q3 revenue of about $1.21 billion and EPS of $3.96, both ahead of analyst expectations. Recurring veterinary diagnostics sales were a growth driver, and the company raised its FY2026 EPS outlook to $14.96–$15.16; revenue guidance is $4.7–$4.8 billion. Reuters article
• Positive Sentiment: Morgan Stanley reiterated an Overweight/Buy view and raised its price target to $810 from $805, citing strong execution and the improved outlook. UBS also characterized the results as strong despite a lackluster veterinary-visit environment. Analyst rating article
• Positive Sentiment: Recent technical coverage noted that IDXX moved above its 200-day moving average, a signal some investors interpret as supportive of a longer-term trend. Zacks technical analysis
• Negative Sentiment: Veterinary visits remain lackluster, and coverage flagged a softer margin outlook. These factors could limit growth or profitability even as diagnostics sales and the full-year earnings forecast improve. Motley Fool article

Analyst Ratings Changes

A number of equities analysts have commented on IDXX shares. KeyCorp initiated coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They issued a “sector weight” rating on the stock. Leerink Partners dropped their target price on IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. UBS Group increased their target price on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research note on Tuesday. Morgan Stanley boosted their price target on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Citigroup increased their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $719.55.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the sale, the director directly owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Institutional Trading of IDEXX Laboratories

A number of large investors have recently bought and sold shares of the business. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $25,000. Elevation Wealth Partners LLC lifted its holdings in IDEXX Laboratories by 188.2% in the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after buying an additional 32 shares during the period. Pension & Wealth Management Advisors Inc. bought a new stake in IDEXX Laboratories in the third quarter valued at $29,000. Arlington Trust Co LLC raised its holdings in shares of IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after acquiring an additional 19 shares during the last quarter. Finally, Bell Investment Advisors Inc grew its position in IDEXX Laboratories by 45.5% in the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after purchasing an additional 20 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

The company has a market cap of $52.94 billion, a PE ratio of 45.32 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.87 and a current ratio of 1.19. The company’s 50 day moving average price is $538.81 and its 200-day moving average price is $573.69.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.